Nykode Therapeutics AS 2025 AR2
The report outlines Nykode's strategic focus on its three core assets, prioritizing its lead clinical cancer immunotherapy candidate, abi-suva. In 2025, the company published positive final Phase 2 data for advanced cervical cancer and prepared for the randomized Phase 2 Abili-T trial in head and neck cancer. Nykode also advanced its individualized neoantigen therapy, VB10.NEO, and its Antigen-Specific Immune Tolerance platform. Financially, the company maintained a disciplined approach, ending the year with a cash position of USD 60.3 million.
Company: Nykode Therapeutics AS
Sector: Professional & technical services
Country: Norway
Year: 2025
Type: AR2
Pages: 101
Back to company
Nykode Therapeutics AS
Annual Report
The report outlines Nykode's strategic focus on its three core assets, prioritizing its lead clinical cancer immunotherapy candidate, abi-suva. In 2025, the company published positive final Phase 2 data for advanced cervical cancer and prepared for the randomized Phase 2 Abili-T trial in head and neck cancer. Nykode also advanced its individualized neoantigen therapy, VB10.NEO, and its Antigen-Specific Immune Tolerance platform. Financially, the company maintained a disciplined approach, ending the year with a cash position of USD 60.3 million.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees